Neuranics, an innovative healthcare diagnostics startup, has successfully raised $700K in its seed funding round, led by Inflection Point Ventures (IPV). The fresh capital will fuel the company’s technology development and clinical validation efforts, moving it closer to its goal of commercial production following the anticipated CDSCO licensing.
Founded in 2021 by Praveen Kumar and Ashutosh Patra, Neuranics is focused on developing a cutting-edge point-of-care blood analyzer. This device is designed to provide complete blood count (CBC) results in under 10 minutes, utilizing just a finger-prick sample. Aimed primarily at primary care and emergency settings, the device offers significant advantages in terms of low maintenance and efficiency, marking it as a potential game-changer for the healthcare industry.
The technology’s impact goes beyond speed—it can enable quick detection of critical conditions like sepsis, severe anemia, and thrombocytopenia, which is especially crucial for dengue patients. By facilitating the rapid initiation of life-saving treatments, Neuranics ensures that timely and effective care is provided to those in need.
Neuranics has already made impressive strides, with the company securing a granted patent, receiving the CDSCO Test License, and obtaining Ethical Approval from AIIMS Delhi. The product is currently progressing through clinical trials, positioning the company for significant growth in the healthcare diagnostics market.
Inflection Point Ventures, a key investor, has been instrumental in backing over 210 startups and has invested more than Rs 790 crore to date, further emphasizing the promise Neuranics holds in transforming healthcare delivery.
